Top-News
Pharmazeutika Israel

XTL Biopharmaceuticals ADR News

Aktie
WKN:  A2DK34 ISIN:  US98386D3070 US-Symbol:  XTLB
2,36 €
-0,04 €
-1,67%
03.05.24 21:43:40
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
4,36 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website

XTL Biopharmaceuticals ADR News

13.02.17 - PR Newswire
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome PR Newswire
25.01.17 - PR Newswire
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program PR Newswire
19.12.16 - PR Newswire
XTL Biopharmaceuticals to Present at Biotech Showcase
XTL Biopharmaceuticals to Present at Biotech Showcase PR Newswire
09.11.16 - PR Newswire
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements PR Newswire
07.09.16 - PR Newswire
XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1
XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1 PR Newswire
06.09.16 - PR Newswire
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016 PR Newswire
11.08.16 - PR Newswire
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1 PR Newswire
05.12.12 - PR Newswire
Following the Acquisition of the Controlling Stake by XTL, Proteologics Appoints Board Members and Chairman
Following the Acquisition of the Controlling Stake by XTL, Proteologics Appoints Board Members and Chairman PR Newswire
26.11.12 - PR Newswire
XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd.
XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd. PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »